A review of preliminary trial data presented at the 2006 ESC/WCC meeting highlighted the effects of perindopril, immune modulation therapy, and telemonitoring in patients with heart failure.
What are the preliminary findings of the PEP-CHF, ACCLAIM, and HHH trials regarding treatments for heart failure?
Preliminary reports from three heart failure trials highlight potential benefits of perindopril in diastolic HF, while immune modulation and telemonitoring did not meet their primary endpoints.
This article provides information and a commentary on trials relevant to the pathophysiology, prevention and treatment of heart failure, presented at the joint European Society and World Congress of Cardiology meeting held in Barcelona in September 2006. All reports should be considered as preliminary data, as analyses may change in the final publication. The PEP-CHF study suggests that perindopril improves symptoms and functional capacity and may reduce heart failure hospitalisations in patients with diastolic heart failure. Although immune modulation therapy failed to reduce the incidence of all-cause mortality and cardiovascular hospitalisations in the ACCLAIM study, the observed differences in outcome in some heart failure patients warrants further investigation. The HHH study failed to show a beneficial effect of telemonitoring over usual care in patients with heart failure but potentially important country interactions were observed.
Cleland et al. (Sun,) conducted a review in Heart failure. Perindopril, immune modulation therapy, and telemonitoring was evaluated. A review of preliminary trial data presented at the 2006 ESC/WCC meeting highlighted the effects of perindopril, immune modulation therapy, and telemonitoring in patients with heart failure.